Barclays analyst Gena Wang initiated coverage of Cytokinetics (CYTK) with an Overweight rating and $55 price target The firm says the company has a “differentiated” cardiac myosin inhibitor in hypertrophic cardiomyopathy. The analyst sees a high probability of approval for Cytokinetics’ lead asset aficamten by the FDA action date of September 26 in obstructive hypertrophic cardiomyopathy. Barclays expects the commercial launch to surpass Camzyos’ initial growth trajectory.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive
- Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
- Cytokinetics Hold Rating: Competitive Challenges and Market Dynamics
- Insider Moves: Cytokinetics, Bj’s, Gran Tierra, PBF, Immunovant
- Cytokinetics’ Market Challenges and Neutral Outlook Amid MAPLE Trial Anticipations